1. Home
  2. VKTX vs ACLX Comparison

VKTX vs ACLX Comparison

Compare VKTX & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viking Therapeutics Inc.

VKTX

Viking Therapeutics Inc.

HOLD

Current Price

$35.63

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Arcellx Inc.

ACLX

Arcellx Inc.

HOLD

Current Price

$63.88

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VKTX
ACLX
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.2B
IPO Year
2015
2022

Fundamental Metrics

Financial Performance
Metric
VKTX
ACLX
Price
$35.63
$63.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
8
Target Price
$87.07
$115.71
AVG Volume (30 Days)
2.4M
1.2M
Earning Date
02-04-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$35,898,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$293.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.92
$47.86
52 Week High
$43.55
$94.07

Technical Indicators

Market Signals
Indicator
VKTX
ACLX
Relative Strength Index (RSI) 47.54 32.48
Support Level $36.00 $63.48
Resistance Level $37.83 $66.79
Average True Range (ATR) 1.46 2.47
MACD -0.02 0.22
Stochastic Oscillator 37.53 3.76

Price Performance

Historical Comparison
VKTX
ACLX

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

About ACLX Arcellx Inc.

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Share on Social Networks: